Gene therapy for renal cell carcinoma (Shire)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGene therapy for renal cell carcinoma (Shire)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionInterleukin-2 modulators
TargetsInterleukin-2
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesShire Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShire Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A